The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Most studies agree on a Cretaceous age for the most recent common ancestor of modern birds but estimates range from the Early Cretaceous to the latest Cretaceous. Similarly, there is no agreement on whether most of the early diversification of modern birds occurred in the Cretaceous and associated with breakup of the supercontinent Gondwana or occurred later and potentially as a consequence of the Cretaceous–Palaeogene extinction event. This disagreement is in part caused by a divergence in the evidence. Most molecular dating studies suggests a Cretaceous evolutionary radiation, while fossil evidence points to a Cenozoic radiation (the so-called 'rocks' versus 'clocks' controversy). The discovery in 2005 of Vegavis from the Maastrichtian, the last stage of the Late Cretaceous, proved that the diversification of modern birds started before the Cenozoic era. The affinities of an earlier fossil, the possible galliform Austinornis lentus, dated to about 85 million years ago, are still too controversial to provide a fossil evidence of modern bird diversification. In 2020, Asteriornis from the Maastrichtian was described, it appears to be a close relative of Galloanserae, the earliest diverging lineage within Neognathae. Attempts to reconcile molecular and fossil evidence using genomic-scale DNA data and comprehensive fossil information have not resolved the controversy.
and Israeli efforts to supply the Contras with arms, the U.S. ignored Noriega's use of weapons-shipment networks to smuggle drugs into the U.S. Noriega was reported to have played a role in the Iran–Contra affair in the mid-1980s. There are varying reports about how much Noriega was paid by United States sources. In early 1990, Noriega biographer Frederick Kempe reported that the United States gave Noriega or his intelligence services annual payments in the range of $110,000 in 1976 increasing to $185,000 to $200,000 when he came to power during the Reagan administration. Dinges said that he could find no one willing to confirm persistent reports that he received a $200,000 per year stipend from the CIA. Prior to and during Noriega's trial, Noriega's lead attorney Frank A. Rubino claimed that Noriega had received $11 million in payments from the CIA. In January 1991, federal prosecutors filed a financial report indicating that Noriega had received a total of $322,000 from the United States Army and the CIA over a 31-year period from 1955 to 1986. They stated that the release of information was to rebut allegations from defense attorneys that Noriega had been paid "millions of dollars" from the CIA. These payments included a total of $76,039 as "gifts and incentives" from the CIA. Despite Noriega's alliance with the U.S., he also maintained close relationships with bitter enemies of the U.S., including Cuba, Libya, and Nicaragua.
Dietary supplements containing ephedra alkaloids are unsafe, with reports of serious side effects and ephedra-related deaths. In response to accumulating evidence of adverse effects and deaths related to ephedra, the U.S. Food and Drug Administration (FDA) banned the sale of supplements containing ephedrine alkaloids in 2004. The ban was challenged in court by ephedra manufacturers, but ultimately upheld in 2006 by the U.S. Court of Appeals for the Tenth Circuit. Ephedra extracts not containing ephedrine have not been banned by the FDA and are still sold legally.
In his work with the late Hans Eysenck and subsequently with Con Stough on the role of basic information processing speed in human intelligence, he used ERP complexity measures to argue for a modification to the Hendrickson and Hendrickson error or "string theory" (so named as pins and string were used to make the measurements of EEG output) model of ability, to include a controlling role of attention. In related work on reaction time, he introduced a novel modification to the Jensen box, again controlling the role of attention in this task, and suggesting that under these conditions, intelligence is, as Arthur Jensen proposed, related to the rate of information processing defined in Fitts Law and using Claude Shannon's information metrics. At the University of Edinburgh he has investigated individual differences in intelligence, memory, and the genetic and environmental influences on social behaviours, such as coalition affiliation, politics, and altruism. Working with Ian Deary, Paul Irwing, and Geoff Derr, he reported evidence for substantial gender differences in intelligence in the form of much larger variance amongst males than amongst females, with more boys and men scoring in both the extreme high range, and in the extreme low range.
February 2: Decree establishing an agricultural action committee in every rural municipality and cantonal agricultural organization committees; women managing such farms have the right to vote in these committees. December 27: Law increasing penalties for specific forms of vagrancy; this notably concerns procuring. 1917
Sources: en.wikipedia.org
=== Wellman Plastics === All characters below appear in the first season and part of the second season before being written out altogether. Clooney would make one more appearance in a season four episode.
An enzyme inhibitor is a molecule that binds to an enzyme and blocks its activity. Enzymes are proteins that speed up chemical reactions necessary for life, in which substrate molecules are converted into products. An enzyme facilitates a specific chemical reaction by binding the substrate to its active site, a specialized area on the enzyme that accelerates the most difficult step of the reaction. An enzyme inhibitor stops ("inhibits") this process, either by binding to the enzyme's active site (thus preventing the substrate itself from binding) or by binding to another site on the enzyme such that the enzyme's catalysis of the reaction is blocked. Enzyme inhibitors may bind reversibly or irreversibly. Irreversible inhibitors form a chemical bond with the enzyme such that the enzyme is inhibited until the chemical bond is broken. By contrast, reversible inhibitors bind non-covalently and may spontaneously leave the enzyme, allowing the enzyme to resume its function. Reversible inhibitors produce different types of inhibition depending on whether they bind to the enzyme, the enzyme-substrate complex, or both. Enzyme inhibitors play an important role in all cells, since they are generally specific to one enzyme each and serve to control that enzyme's activity. For example, enzymes in a metabolic pathway may be inhibited by molecules produced later in the pathway, thus curtailing the production of molecules that are no longer needed. This type of negative feedback is an important way to maintain balance in a cell.
== External links == "Opioid Receptors: μ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.
=== Amine hormones === Hormones derived from the modification of amino acids are referred to as amine hormones. Typically, the original structure of the amino acid is modified such that a –COOH, or carboxyl, group is removed, whereas the –NH+3, or amine, group remains. Amine hormones are synthesized from the amino acids tryptophan or tyrosine.
=== Israeli stamps === Kuwait, Lebanon, Libya, and Yemen do not allow entry to people with passport stamps from Israel or whose passports have either a used or an unused Israeli visa, or where there is evidence of previous travel to Israel such as entry or exit stamps from neighbouring border posts in transit countries such as Jordan and Egypt. To circumvent this Arab League boycott of Israel, the Israeli immigration services have now mostly ceased to stamp foreign nationals' passports on either entry to or exit from Israel (unless the entry is for some work-related purposes). Since 15 January 2013, Israel no longer stamps foreign passports at Ben Gurion Airport. Passports are still (as of 22 June 2017) stamped at Erez when passing into and out of Gaza. Iran refuses admission to holders of passports containing an Israeli visa or stamp that is less than 12 months old.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.